

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Human Lymphocytes and *Drosophila melanogaster*¹ as Model System to Study Oxidative Stress in Parkinson's Disease

Marlene Jimenez-Del-Rio and Carlos Velez-Pardo
 School of Medicine, Medical Research Institute, Neuroscience Research Group,
 University of Antioquia,
 Medellin,
 Colombia

1. Introduction

Parkinson's disease (PD, OMIM entry #168600) is the most common progressive neurodegenerative disorder that not only affects a large group of individuals in Antioquia, Colombia (Pradilla et al., 2003; Sanchez et al., 2004) but also affects other regions in the world. Actually, the prevalence of PD is between 0.1% and 0.3% in the general population and between 1% and 2% in persons 65 years of age or older (Alves et al., 2008). Moreover, the number of individuals with PD over age 50 has been projected between 8.7 and 9.3 million in Western countries by 2030 (Dorsey et al., 2007). PD is typified clinically by motor symptoms including bradykinesia, resting tremor, rigidity and gait posture abnormalities followed by postural instability and less frequent non-motor complication such as dementia, depression and autonomic dysfunction (Jancovic, 2008). Pathologically, the disorder is prominently characterized by progressive loss of 50–70% of dopaminergic neurons located in the substantia nigra, decrease of the neurotransmitter dopamine content in striatum (Forno, 1996), cytoplasmic inclusions of insoluble, aggregated proteins, including α -synuclein known as Lewy bodies (Cuervo et al., 2010), elevated levels and/or deposits of iron (Sian-Hülsmann et al., 2010) and selective neuronal vulnerability to oxidative stress (Wang & Michaelis, 2010). The cause of all cases of PD remains unknown. However, in the mid-1990s this situation changed with the identification of a mutation in the α -synuclein gene associated with autosomal dominant PD in Italian kindred (Polymeropoulos et al., 1997). Since then, more than 10 genes have been found either causal of the disease (e.g., *Parkin*, *DJ-1*, PTEN-induced putative kinase 1 (*PINK-1*), leucine rich region kinase 2 (*LRRK2*), *ATP13A2* (Xiromerisiou et al., 2010; Cookson, 2010; Hardy, 2010)) or as risk factor for PD (e.g. HLA region). Interestingly, the first gene that causes autosomal recessive

¹*Drosophila melanogaster* has misleadingly been known as the fruit fly. Strictly, "...real fruit flies,...attack unblemished fruit and in heavy infestations cause serious economic damage. In contrast, even if present in enormous numbers, *D. melanogaster* is innocuous and of no economic importance" (Green, MM. (2002). It really is not a fruit fly, *Genetics* 162: 1-3). It is therefore most adequate to name *Drosophila melanogaster* as just *Drosophila melanogaster* fly

juvenile Parkinsonism (AR-JP) was reported and named *parkin* in 1998 by Kitada and colleagues. AR-JP maps to the long arm of chromosome 6 (6q25.2-q27). The *parkin* gene is composed of 2,960 base pairs with a 1,395-base-pair open reading frame encoding for a protein of 465 amino acids with moderate similarity to ubiquitin at the amino terminus and a RING-finger motif at the carboxy terminus. The gene spans more than 500 kilobases and has 12 exons (Kitada et al., 1998). Subsequent studies have shown that *parkin* is a RING-finger-containing protein identified as an E3 protein-ubiquitin ligase (Shimura et al., 2000), which is an integral component of the cytoplasmic ubiquitin/ proteosomal degradation pathway (Betarbet et al., 2005). The reaction promoted by E3 ligases is the addition of a lysine-linked chain four or more ubiquitin molecules to the target protein, which is recognised by the subunits in the proteasome. Thus, mutation of the *parkin* gene could result in accumulation of misfolded proteins (Tanaka et al., 2001; Imai and Takahashi, 2004). Therefore, it is hypothesized that mutations in *parkin* gene, which result in loss of function, are unable to remove enough mutated or misfolded proteins leading to nigral neurodegeneration. Moreover, the Parkin protein may play a role in promoting autophagy of dysfunctional mitochondria following loss of mitochondrial membrane potential (Bueler, 2010).

Currently, AR-JP (OMIM entry #600116) is considered a distinct genetic entity characterised by early age at onset (<age 45), dystonia with parkinsonism and improvement of symptoms after sleep, slow disease progression, associated signs such as hyperflexia, dysautonomia, peripheral neuropathy and good response to low doses of L-DOPA (Zhang et al., 2001). Additionally, iron deposits are found in PD (Dexter et al., 1989; Sofic et al., 1991; Riederer et al., 1992; Griffiths et al., 1999) as well as in AR-JP (Takanashi et al., 2001). Why dopaminergic neurons in the substantia nigra are particularly vulnerable to the loss of parkin function and iron deposition is yet unknown. To date, the most common known form of hereditary Parkinsonism, i.e. AR-JP, diagnosed in Antioquia, Colombia is due to the *parkin* C212Y mutation. This mutation is a novel G to A transition in exon 6 at position 736 (G736A) of *parkin* gene. The C212Y mutation was identified in a genetic isolate community from two Paisa family groups (PJF-1, PJF-3) by Pineda-Trujillo et al., (2001). Interestingly, the mutation was subsequently observed in a Spanish family, suggesting that it could have been taken to Antioquia by Spanish immigrants. Pineda-Trujillo et al., (2006) screened for the G736A mutation in additional Antioquian early onset PD cases and used haplotype analysis to investigate the relationship between Spanish and Antioquian G736A chromosomes. They confirmed the occurrence of an extensive founder effect in Antioquia. Thirteen individuals (10 homozygotes) from seven nuclear families were identified with the G736A mutation. Genealogical investigations demonstrated the existence of shared ancestors between six of these families four to five generations ago and no evidence of Spanish ancestry during this period. A second *parkin* mutation (a duplication of exon 3), was detected in the three G736A heterozygote carriers. Haplotype data exclude a recent common ancestry between the Spanish and Antioquian patients studied and are consistent with the introduction of the G736A mutation in Antioquia during early colonial times by about 16 generations ago. Further studies have also confirmed the presence of a GT insertion in exon 3 mutation among Paisa community previously identified in Spanish and French families with juvenile Parkinsonism (Pineda-Trujillo et al., 2001, 2009). Strikingly, the proteins that are reported to be related to familial PD such as PINK1, DJ-1, α -synuclein, LRRK2 and possibly parkin are either mitochondrial proteins or are associated with mitochondria. Interestingly, all those proteins are involved in pathways that elicit oxidative stress or free radical damage (Lin et al., 2009).

Free radicals are defined as any atom or molecule that has one or more unpaired electrons in its outer shell such as anion superoxide radical ($\cdot\text{O}_2^-$), hydroxyl radical ($\cdot\text{OH}$), nitric oxide ($\text{NO}\cdot$) and their products (e.g. H_2O_2). Oxidative stress (OS) refers to a state in which free radicals are in excess of antioxidant defence mechanism (e. g. superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, vitamin C and E). As a result of this imbalance, the free radicals are capable of reacting with lipids, proteins, nucleic acids, and other molecules altering their structure and function. Accordingly, OS can lead to serious structural modifications in cells by excessive accumulation of oxidized products such as aldehydes and isoprostanes from lipid peroxidation, protein carbonyls from protein oxidation, and base adducts from DNA oxidation. Because the human brain is a high oxygen consumer organ, it is reasonable to assume that, under pathological conditions, it might be a target of permanent OS attack.

Over the last two decades, OS has been proposed to play a critical role in the pathogenesis of PD (Fahn and Cohen, 1992; Jenner & Olanow, 1996; Tsang & Chung, 2009). In fact, several markers of OS have been identified in post-mortem brain tissues including increased levels of DNA and RNA oxidation (e.g. 8-hydroxyl-2-deoxyguanosine and 8-hydroxyl deoxyguanosine), protein carbonyl levels, glycation and glycooxidation, lipid peroxidation and high iron concentration (Zhou et al., 2008). Moreover, given that iron and DA generate reactive oxygen species (ROS), they have been implicated in the OS observed in PD (Asanuma et al., 2004). Not surprisingly, lymphocytes have been used to test for oxidative stress (Battisti et al., 2008) and cell death (Calopa et al., 2010) in PD. For instance, Migliore et al., (2002) has demonstrated an increase in the incidence of spontaneous micronuclei, single strand breaks and oxidized purine bases in PD patients without treatment. These results clearly showed oxidative DNA damage demonstrable in lymphocytes. Moreover, we found that homozygote Cys212Tyr *parkin* mutation in AR-JP patients renders lymphocytes sensitive to dopamine, iron and hydrogen peroxide stimuli (Jimenez-Del-Rio et al., 2004). In agreement with these findings, Prigione and co-workers (2009) have shown increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Interestingly, Jiang et al., (2004) have shown that *parkin* protects human dopaminergic neuroblastoma cells against dopamine-induced cell death. Taken together these data suggest that analysis of DNA or lymphocytes response against oxidative stress might be used as an early marker of the OS status in PD patients.

Despite these evidences, there are still major unresolved issues in the understanding of the molecular and cellular biology of PD. Indeed, a complete picture of the precise molecular cascade leading to cell death in a single cellular model in this disorder is still lacking. Therefore, we have been interested in investigating the oxidative stress phenomenon and apoptosis signalling in lymphocytes and *Drosophila melanogaster*.

2. *In vitro* and *In vivo* models

2.1 Human lymphocytes resemble neuronal cells

The brain and the immune system are involved in functionally relevant cross-talk influencing one another's actions, whose main function is to maintain homeostasis. Therefore, to play such a role, lymphocytes are equipped with several biochemical systems that display comparable pathways to neural cells. This unusual characteristic makes lymphocytes an excellent *in vitro* model (Massaud et al., 1998; Kriesberg, 2011) to understand normal and abnormal function from gene to phenotype. Moreover, lymphocytes

might provide the basis of biochemical and cytopathological mechanisms for preventive or therapeutic intervention. These cells thus appear to be particularly fascinating cell model for PD at least for three main reasons. First, lymphocytes express six homologous neurochemical systems (Table).

System	Protein Expression
1. Dopaminergic	Tyrosine hydroxylase & monoamine oxidase (Marino et al., 1999 & references within); dopamine transporter (Amenta et al., 2001; Marazziti et al., 2010); dopamine D2-, D3-, D4-, D5-like receptors (Ricci & Amenta, 1994; Ricci et al., 1995, 1997; Amenta et al., 1999; McKenna et al., 2002).
2. Serotonergic	Serotonin transporter (SERT, Faraj et al., 1991; Marazziti et al., 2010); serotonin receptors (Stefulj et al, 2000); tryptophan hydroxylase (Carrillo-Vico et al., 2004).
3. Cholinergic	Acetylcholine (Ach), muscarinic and nicotinic Ach receptors (mAChRs and nAChRs), choline acetyltransferase (ChAT), high affinity choline transporter and acetylcholinesterase (Kawashima & Fujii, 2004).
4. Glutamatergic	Ionotropic glutamate receptors (Lombardi et al., 2001, 2004); group I metabotropic glutamate receptors (Miglio et al., 2005).
5. Adrenergic	β -2 adrenergic receptors (Sanders, 1998).
6. Gabaergic	γ -aminobutyric acid (GABA) receptors (Tillakaratne et al., 1995).

Table 1. Neuronal Molecular systems expressed in lymphocytes.

Second, lymphocytes express similar molecular death machinery leading to typical morphologic and biochemical features of apoptosis. Apoptosis is a type of programmed cell death initially defined by Kerr and co-workers in 1972 and recently refined by several others (Kerr et al., 1995; Xu & Shi, 2007; Kroemer et al., 2009). Apoptosis is originally a morphological phenomenon characterised by chromatin condensation and nuclear fragmentation, plasma membrane blebbing, cell shrinkage and preservation of organelles such as mitochondria. These characteristics can be recognised in lymphocytes under fluorescent microscopy (Fig. 1) or electron microscopy (Sakahira et al., 1999; Marini et al., 2001). Noticeably, what causes these morphological changes that we recognize as apoptosis occurs through multiple independent pathways that are initiated either from triggering events within the cell (i.e the “intrinsic pathway”) or from outside the cell (i.e. the “extrinsic pathway”). The “intrinsic pathway” involves the release of mitochondrial proteins such as cytochrome C, second mitochondrial-derived activator of caspase/direct IAP-associated binding protein with low PI (Smac/DIABLO), apoptosis inducing factor (AIF) and Endonuclease G (Endo G). The “extrinsic pathway” involves Fas/FasL pathway, caspase-8 activation, bid degradation and releasing cytochrome C. Strikingly, both pathways converge

on a common machinery of cell dismantling executed by a family of cysteine proteases known as Caspases. Indeed, caspases cleavage at aspartate residues of targeted proteins (Chowdhury et al., 2008). Particularly, caspase-3 degrades the inhibitor of caspase-activated DNase (ICAD/ DNA fragmentation Factor-45, DFF-45) protein releasing the caspase-activated DNase (CAD/ DFF-40) that result in DNA degradation ("DNA ladder pattern") from mouse T-cell lymphoma (Enari et al., 1998; Sakahira et al. 1998), Jurkat T cells (Liu et al, 1997) and HeLa cells (Halenbeck et al., 1998) under pro-apoptotic treatments. It is worth to mention that almost 18-years passed before an explanation could be drawn for one of the earliest well-recognized biochemical characteristics of apoptosis i.e. "DNA ladder pattern", from the time when Wyllie reported glucocorticoid-induced thymocytes apoptosis associated with endonuclease activation (Wyllie, 1980). Unquestionably, morphological and biochemical data have helped considerably to enlighten, yet unsettled, the mechanism of neural cell death in PD (Levy et al., 2009).




Fig. 1. **Human lymphocytes treated with xenobiotic paraquat, PQ for 24h.** Figure shows typical nuclear apoptotic morphology such as highly condensed chromatin (arrows) and nuclear fragmentation (arrowheads) from lymphocytes treated with PQ compared to normal nuclei (asterisk) stained with acridine orange/ ethidium bromide. A similar apoptotic morphology can be observed with dopamine, DA; 6-hydroxydopamine, 6-OHDA; 5,6 & 5,6 dihydroxydopamine, 5,6 & 5,7-DHT; rotenone, ROT. Jimenez-Del-Rio & Velez-Pardo, 2008. Reproduced with permission from Informa Healthcare UK Ltd.

Third, lymphocytes and neurons are post-mitotic cells, i.e. they become locked in a G_0 phase of the cell cycle. This is a remarkable biological feature to be cautiously considered when interpreting experimental data since evidence has accumulated that a cell division forced on a mature neuron leads to apoptosis rather than division (Herrup et al., 2004), but cell division is induced in lymphocytes. In other words, the use of cell lines instead of primary cultures could be confusing and /or misleading. For instance, NF- κ B is a transcriptional

factor composed of a p50/p65 heterodimer protein that upon activation binds to specific DNA sequences in target genes, designated as κ B-elements. This factor is involved in both cell cycle-regulation and cell death processes. In dividing cells, NF- κ B transcribes cyclin D1, which in association with cyclin-dependent kinases, CDK4 and CDK6, promotes G1/S phase transition through CDK-dependent phosphorylation of retinoblastoma protein (pRb), thereby releasing the transcription factor E2F, required from the activation of S phase-specific genes. Indeed, constitutive activation of NF- κ B is intimately intertwined with cancer growth and metastasis (Prasad et al., 2010). On the other hand, the regulatory roles of NF- κ B on apoptosis suggest that NF- κ B is acting on the upstream pathways of apoptosis, either negatively or positively (Shishodia & Aggarwal, 2004; Qin et al., 2007). Noticeably, in non-dividing cells, these confounding matters connected with the role of NF- κ B in apoptosis and cell-cycle control might not be an important issue given that NF- κ B function can eventually be studied independently from the cell cycle function. Thus, G₀ represents not simply the absence of signals for mitosis but an active repression of the genes needed for mitosis.

2.1.1 Human lymphocytes as cellular model to study oxidative stress and apoptosis in PD.

Deciphering the Parkinson's disease cascade(s) is one of the ultimate research goals in the PD field not only because it offers the possibility to scrutinize a basic cellular machinery of response to different deleterious stimuli, but also because it brings the possibility to predict novel therapies. Accordingly, we postulated a unified molecular cascade model wherein H₂O₂ is definitely a paramount molecule involved in intracellular signalling that induces neuronal loss in PD (Jimenez-Del-Rio & Velez-Pardo, 2000, 2004a & Fig. 2). Effectively, we were able to clarify the major signalling events by which DA (Jimenez-Del-Rio et al., 2004), monoamine related toxins (e.g. 6-OHDA; 5,6-DHT; 5,7-DHT: Jimenez-Del-Rio & Velez-Pardo, 2002), redox metals such as Fe²⁺, Cu²⁺, Mn²⁺, Zn²⁺ (Jimenez-Del-Rio & Velez-Pardo, 2004b & Fig. 3) and H₂O₂ (Jimenez-Del-Rio & Velez-Pardo, 2006) might induced cell death in normal and/or mutated lymphocytes (e. g. C212Y in parkin) PD.

During the last few years, several reports have been published supporting our findings. Liang et al., (2007) have found that NF- κ B contributes to 6-OHDA-induced apoptosis of nigral dopaminergic neurons through p53. Bernstein and co-worker (2011) have shown that 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Bilobalide, which is a constituent of *Ginkgo biloba* 761, inhibits 6-OHDA-induced activation of NF- κ B and loss of dopaminergic neurons in rat substantia nigra (Li et al., 2008). Importantly, Aleyasin et al., (2004) have shown that acute inhibition of NF- κ B via expression of a stable I κ B mutant, down-regulation of the p65 NF- κ B subunit by RNA interference (RNAi), or pharmacological NF- κ B inhibitors significantly protected against DNA damage-induced neuronal death. NF- κ B inhibition also reduced p53 transcripts and p53 activity as measured by the p53-inducible messages, Puma and Noxa, implicating the p53 tumor suppressor in the mechanism of NF- κ B-mediated neuronal death. Takada et al. (2003) have shown that H₂O₂ activates NF- κ B through tyrosine phosphorylation of I κ B α and serine phosphorylation of p65 by I κ B α kinase and Syk protein-tyrosine kinase. Prabhakaran et al., (2008) have shown that NF- κ B induction and the activation of nitric oxide synthase through ROS represents a proximate mechanism for Mn-induced neurotoxicity. Therefore, we conclude that NF- κ B, p53 and caspase-3 are crucial signalling molecules involved in H₂O₂-induced cell death. Based on this model, we predicted that molecules capable of generating




Fig. 2. **Schematic model of dopaminergic and serotonergic related toxins-induced apoptosis by an oxidative stress mechanism in PBL.** 6-OHDA; 5,6-& 5,7-DHT or protein fragment A β generate H₂O₂. This last compound might activates JNK/SAPK kinases pathway, which in turn activate in parallel both NF- κ B and c-Jun transcription factors. NF- κ B is able to activate the transcriptional factor p53 and subsequently it may activate the pro-apoptotic Bax protein, which induces cytochrome C release from mitochondria to activate the apoptosome complex leading to caspase-3 activation and apoptosis. Jimenez Del Rio and Velez-Pardo, 2002. Reproduced with permission from Elsevier.

H₂O₂ might induce a mechanism resembling the one depicted in Fig. 2. To further test our model, we used paraquat (PQ), also known as methyl viologen dichloride or 1,1'-dimethyl-4,4'-bipyridinium dichloride, and rotenone (ROT), a redox cycling herbicide and a mitochondrial complex I inhibitor as xenobiotic compound generally used to model PD (Bové et al., 2005). We concluded that both PQ-and ROT-induced time- and concentration-dependent apoptosis in lymphocytes which was mediated by anion superoxide radicals (O₂^{•-}) / hydrogen peroxide, depolarization of mitochondria, caspase-3 activation, concomitantly with the nuclear translocation of transcription factors such as NF- κ B, p53, c-Jun and nuclei fragmentation (Fig. 4-5, Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-Gomez




Fig. 3. **Schematic representation of the major molecular events induced by metals in lymphocytes.** Fe^{2+} -metal ions in the presence of molecular dioxygen (1) generate superoxide radicals (2), which dismutate either by enzymatic (e.g., superoxide dismutase, SOD) or spontaneously into H_2O_2 (3). This last compound in turn may react with Fe^{2+} to produce hydroxyl radicals (4) (OH^{\cdot}) by Fenton reaction. Over-production of (OH^{\cdot}) may alter the mitochondria transmembrane potential (5) inducing the liberation of different apoptogenic factors and subsequent activation of caspase-3 (6) resulting in disassembly and fragmentation of nuclear chromatin leading PBL to apoptosis (7). The symbol () represents the inhibition (by indicated compound) of the critical steps of the molecular cascade leading to apoptosis by metal ions. Jimenez-Del-Rio & Velez-Pardo, 2004b. Reproduced with permission from Elsevier.

et al., 2010). Interestingly, Choi et al., (2010) have shown that JNK3 mediates PQ- and ROT-induced dopaminergic neuron death. Remarkably, the cell death routine depicted in Fig. 3 can be reversed by the action of cannabinoids (Jimenez-Del-Rio & Velez-Pardo, 2008), IGF-1 (Avila-Gomez et al., 2010) and glucose (Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010). These data may provide innovating therapeutic strategies to intervene environmentally or genetically susceptible PD population to oxidative stress.

2.1.2 Alternative therapies for parkinson's diseases: a mechanistic igf-1, cannabinoids and glucose proposal

Based on recent progress in delineating the disease cascade and cell death process (Jenner & Olanow, 1998; Blum et al., 2001; Wirths et al., 2004; Jimenez-Del-Rio & Velez-Pardo, 2004a; Green & Kroemer, 2005; Przedborski, 2005; Jimenez-Del-Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010), discrete types of potentially disease modifying treatment could be administered for PD. In this regard, our data have highlighted the potential use of lymphocytes as a model to screen antioxidant strategies designed to remove (Fe^{2+})/(O_2)/(H_2O_2)/(OH^{\cdot}), signalling inhibitors and/or restorative approaches as promising




Fig. 4. Schematic model of the major molecular events induced by PQ in lymphocytes. PQ in the presence of NADH/NADPH reductases (1) is converted into monocationic radical compound which readily react with molecular dioxygen to generate superoxide radicals (2), which dismutate either by enzymatic (e.g. superoxide dismutase, SOD) or spontaneously into H₂O₂ (3) This last compound in turn may activate the mitogen-activated protein kinase kinase kinase (e.g. MEKK1) which can activate both c-Jun (4) via activation of MKK4/JNK, and NF-κB activation (5) via phosphorylation of the IκBa (i.e. the repressor of NF-κB) by the IKK complex. The NF-κB translocates into the nucleus and transcribes p53 protein (6). Consequently, this protein transcribes pro-apoptotic proteins (e.g. Bax) which are able to permeabilize mitochondria, thus, promoting the activation of caspase-3 (7) which signals chromatin fragmentation, typical of apoptotic morphology (8). The symbol () represents the inhibition (by indicated compound) of the critical step of the molecular cascade leading to apoptosis by PQ. Jimenez Del Rio & Velez-Pardo, 2008. Reproduced with permission from Informa Healthcare UK Ltd.




Fig. 5. PQ induces simultaneous activation of the transcription factors in lymphocytes. PBL cells were left untreated (A–C) or exposed to 1mMPQ (D–F) for 24 h. After this time of incubation, cells were stained with anti-NF- κ B-p65 (A and D), anti-p53 (B and E) and anti-c-Jun (C and F) antibodies according to procedure described in Materials and methods. Notice that NF- κ B, p53 and c-Jun positive-nuclei (dark brown color) reflect their nuclear translocation/activation and appear to correlate with the apoptotic nuclear morphology, i.e. condensed/fragmented nuclei when compared with untreated cells (A–C). Magnification 400 \times (A–F). Jimenez-Del-Rio & Velez-Pardo, 2008. Reproduced with permission from Informa Healthcare UK Ltd.

therapy for PD. As depicted in Figs. 2-4, these mechanistic pathways may be of potential use for screening pharmacologically chemical libraries containing hundreds to thousands of compounds each that could modulate or control sensible molecules critical in cell fate (e. g., H_2O_2 , NF- κ B, p53, c-Jun, caspases). Recently, neurotrophic factors have come into focus as potential therapy in PD (Evans et al., 2008). One clue of its neuroprotective capability comes from the fact that IGF-1 is able to activate NF- κ B against H_2O_2 oxidative stress (Heck et al., 1999). However, it has also been shown that NF- κ B activation is involved in H_2O_2 -induced apoptosis (Kutuk & Basaga, 2003). Therefore, the molecular mechanism(s) that explain the dual role of NF- κ B as attenuator or promoter of apoptosis and the IGF-1's molecular mechanism of neuroprotection still remain to be established.

Taken advantage of the fact that human PBL express IGF-1 receptors (Tapson et al., 1988; Kooijman et al., 1992) and IGF-1 appears to be of potential therapeutic use against PD (Quesada et al., 2008), we were interested in the understanding of the molecular events that are thought to be downstream of IGF-1, in relation to the role played by NF- κ B in survival and death-signalisation against PQ, ROT and H_2O_2 in lymphocytes, as a single cell model. We found that (100 nM) IGF-1 protects lymphocytes from (1 mM) PQ, (250 μ M) ROT and (25, 50, 100 μ M) H_2O_2 -induced apoptosis through NF- κ B activation and p53 down regulation involving the phosphoinositide 3-kinase (PI-3K)-dependent pathway. Interestingly, IGF-1, PDTC (a NF- κ B inhibitor) and pifithrin- α (PFT, a p53 inhibitor) were able to protect and rescue lymphocytes pre-exposed to PQ even when the three compounds were added up-to 6 h post-PQ exposure. Overall these observations suggest that survival and rescue of

lymphocytes from PQ and ROT toxicity is determined by p53 inactivation via IGF-1/ PI-3K pathway (Jimenez Del Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010).

Which molecular mechanism(s) explain the dual role of NF- κ B as an attenuator or promoter of apoptosis? NF- κ B has been reported to activate both pro-apoptotic genes such as p53 transcription factor (Wu & Lozano, 1994; Hellin et al., 1998; Jimenez Del Rio & Velez-Pardo, 2002; Velez-Pardo et al., 2002; Aleyasin et al., 2004), which in turn activates the expression of several genes that directly control or regulate the process of apoptosis such as Bax, which is a pro-apoptotic Bcl-2 protein family (Xiang et al., 1998), and anti-apoptotic genes such as Bcl-2, Bcl-X_L, X-linked inhibitor of apoptosis (Kairisalo et al., 2009). Therefore, one prevailing model proposes that when the molecular ratio of pro-survival (e.g. Bcl-2, Bcl-xL, Bcl-w) to pro-death Bcl-2 family members (e.g. Bax, Bad, Bak, Bid) is biased towards pro-death Bcl-2 family members either through changes in expression level, localization or activity, the outer mitochondrial membrane becomes permeable to apoptogenic proteins resulting in the activation of a cascade of effector caspases, such as caspase-3, that kill the cells by irreversible proteolysis of critical nuclear and cytoplasmic constituents. In this vein, our data suggest that IGF-1 might promote gene transcription of survival genes via NF- κ B activation (Kane et al., 1999) and suppresses gene transcription of pro-apoptotic proteins through p53 inactivation. How then p53 turn-off could be related with IGF-1 citoprotection? One possible explanation for this phenomenon comes from the work by Ogawara and colleagues (2002) who showed that Akt enhances the ubiquitination-promoting function of Mdm2 (murine double minute) by phosphorylation of S¹⁸⁶, which results in reduction of p53 protein. Furthermore, Feng and colleagues (2004) showed that PKB/ Akt induces phosphorylation of Mdm2 at Ser¹⁶⁶ and Ser¹⁸⁸ resulting in Mdm2 protein stabilization. Based on this information and our data, it is reasonable to assume that p53 is modulated by IGF-1 through PI3K-Akt pathway. In fact, our findings reveal that p53 but not NF- κ B is the critical transcription factor that may possibly balances the expression of pro-death proteins towards intracellular death decision under oxidative noxious stimuli (Lu, 2005). Therefore, an ideal natural or synthetic pharmacological compound would be one that efficiently function as an antioxidant (e.g. 17 β -estradiol (Jimenez-Del-Rio & Velez-Pardo, 2001; vitamin E) and simultaneously act as a survival signalling molecule (e.g. IGF-1). To our surprise, the molecules exhibiting both features might come from the glandular hairs of *Cannabis sativa* or marijuana, actually known as cannabinoids.

2.1.2.1 Cannabinoids

Cannabinoids are a group of C₂₁ terpenophenolic compounds (Elsohly & Slade, 2005), which exert their effects by binding to specific plasma membrane G-protein-couple receptors, termed CB1 (Matsuda et al., 1990) and CB2 (Munro et al., 1993) receptors. Activation of these receptors has been shown to trigger several G_{i/o}-protein-mediated signalling pathways (Turu & Hunyady, 2010). Although, it is currently accepted that CB1 receptors are specially abundant in basal ganglia, hippocampus, cerebellum and cortical structures; and CB2 receptors are restricted to cell types related to the immune function such as spleen macrophages, tonsils, B cells and natural killer cells, monocytes, neutrophils, and T cells (Pazos et al., 2005), it has also been demonstrated the existence of CB2 receptors in purkinje cerebellar neurons (Skaper et al., 1996), microglia (Klegeris et al., 2003), oligodendrocytes (Molina-Holgado et al., 2002) and brainstem neurons (Van Sickle et al., 2005). Moreover, both receptors elicit similar signalling pathways such as inhibition of adenylate cyclase, stimulation of extracellular-signal-regulated kinase (Demuth & Molleman, 2006) and

activation of phosphoinositide 3-kinase/PKB (Gomez Del Pulgar et al., 2000; 2002; Molina-Holgado et al., 2002; Sanchez MG et al., 2003). The physiological significance of these common characteristics is still unknown.

Cannabinoids have been proposed as potential therapeutic agents against PD (García-Arencibia et al., 2009) thanks to their involvement in control of cell death/ survival decision and in neuroprotection (van der Stelt & Di Marzo, 2005). However, the mechanism of both actions by cannabinoids is far from clear. Moreover, cannabinoids have been shown to function as antioxidant compounds via receptor-independent (Hampson et al., 1998; Chen et al., 2000; Marsicano et al., 2002) or receptor-dependent mechanisms (Nagayama et al., 1999; Kim et al., 2005) or both mechanisms (Kaplan et al., 2003). Although CB antagonists (v. gr. SR141716A) have been used to elucidate the neuroprotective mechanism of cannabinoids, they have not been conclusive (see Marsicano et al., 2002 versus Nagayama et al., 1999; Kim et al., 2005). Therefore, the molecular mechanism(s) of cannabinoids effect on cells is a complex and still controversial issue.

Despite intense investigation, the detailed intracellular mechanism(s) involved in cannabinoids survival effect remains to be elucidated. Because CB2 cannabinoid receptor is linked to activation of PI3K (Sanchez MG et al., 2003), and the non-classical cannabinoid (-)-CP55,940 (a CB1 and CB2 agonist) and JWH-015 (a CB2 agonist) are commercially available, we wanted to elucidate the molecular signalling downstream of CB2 receptor linked to the role played by NF- κ B and p53 in survival and death-signalisation against oxidative stress stimuli. We found that both synthetic agonists protect and rescue PBL against A β ₂₅₋₃₅- and PQ-induced apoptosis by receptor-independent and receptor-dependent pathway (Velez-Pardo & Jimenez-Del-Rio, 2006; Jimenez Del Rio & Velez-Pardo, 2008). In agreement with our previous observations with IGF-1, these results suggest that CP55,940 / (JWH-015) protective and rescue effect on PBL from noxious stimuli is determined by p53 inactivation. Recently, we investigated the ability of CP55,940 and JWH-015 to scavenge reactive oxygen species and their effect on mitochondria permeability transition (MPT) in either a mitochondria-free superoxide anion generation system, intact rat brain mitochondria or in sub-mitochondrial particles (SMP) treated with PQ. Oxygen consumption, mitochondrial membrane potential ($\Delta\psi_m$) and MPT were determined as parameters of mitochondrial function. It was found that both cannabinoids effectively attenuate mitochondrial damage against PQ-induced oxidative stress by scavenging anion superoxide radical (O₂^{•-}) and hydrogen peroxide (H₂O₂), maintaining $\Delta\psi_m$ and by avoiding Ca²⁺-induced mitochondrial swelling (Velez-Pardo et al., 2010). Understanding the mechanistic action of cannabinoids on mitochondria might provide new insights into more effective therapeutic approaches for oxidative stress related disorders (Fig. 6). Further investigation is needed to classify cannabinoids molecules (Padgett, 2005; Thakur et al., 2005) with effective anti-oxidant from those with pro-oxidant actions.

2.1.2.2 Glucose

Glucose is a soluble sugar added to all cell culture media. In fact, glucose entry to the cell is facilitated by glucose transporters (GLUTs 1-13) (Manolescu et al., 2007) and depending on cell type, the amount of glucose in cell culture formulations ranges from 1 g/L (5.5 mM) to as high as 10 g/L (55 mM). This is an important consideration to take into account because the same processes that can affect cells and molecules *in vitro* can occur *in vivo*. Lymphocytes are ideal for learning about glucose metabolism and resistance against oxidative stress for several reasons. First, these cells express GLU-1 and GLU-3 transporter proteins




Fig. 6. Scheme of proposed cannabinoid mechanism of action against Paraquat-induced mitochondrial oxidative stress. High mitochondrial membrane potential ($\Delta\Psi_m$) in intact rat brain mitochondria drives PQ compound into the mitochondrial matrix. Once inside, (1) PQ is reduced to the monocation radical $PQ^{\cdot-}$ at complex I in the respiratory chain by electrons donated from NADH. $PQ^{\cdot-}$ reacts rapidly with O_2 to produce superoxide ($O_2^{\cdot-}$), thereby consuming high amount of oxygen. In turn, the ($O_2^{\cdot-}$) is enzymatically dismutated by MnSOD into H_2O_2 . Then, H_2O_2 induces mitochondrial permeability transition pore (MPT) and decreases $\Delta\Psi_m$. Interestingly, when cannabinoids are present (2), they can remove both $O_2^{\cdot-}$ and H_2O_2 thereby blocking further ROS signaling. Most interestingly, cannabinoids inhibit MPT probably through interactions with the cyclosporine A-binding cyclophilin-D protein (black circle). As a result, cannabinoids maintain the MPT-multiprotein complex (MPC) in a close-stated, high ($\Delta\Psi_m$) but O_2 consumption is still high. Taken in conjunction these actions, cannabinoids thus protect mitochondria from further damage. Velez-Pardo et al., 2010. Reproduced with permission from Springer Publishers Ltd.

(Piatkiewicz et al., 2007). Second, glucose metabolism in lymphocytes is a regulated process. Indeed, glucose can enter glycolytic, pentose phosphate and Krebs cycle pathways (Maciver et al., 2008). Therefore, these cells represent a remarkable non-neural cell model to understanding metabolic regulation of apoptosis and cell survival signaling against stressful stimuli.

Previously, we have demonstrated that PQ- and ROT- induce apoptosis in lymphocytes cultured in standard RPMI 1640 culture medium, which contains 11 mM glucose (11G), via a cascade of molecular events involving $O_2^{\cdot-}$ and H_2O_2 , as prime death signals (Jimenez-De-Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010). Interestingly, by increasing the concentration of glucose to 55 mM (55G) in RPMI 1640 culture medium, it has been shown

that glucose almost completely protected lymphocytes against PQ- and ROT-induced apoptotic cell death (Jimenez-De-Rio & Velez-Pardo, 2008; Avila-Gomez et al., 2010). These data thus suggest that the predominance of PQ- and ROT-induced oxidative stress damage may be adjusted by decreasing or increasing the concentration of glucose in the cell culture media. By using biochemical analysis and pharmacological inhibition, we found that 55G was effective in suppressing rotenone-induced apoptosis in lymphocytes via four acting pathways which involve the pentose phosphate pathway (PPP-II), glutathione pathway, SOD and CAT antioxidant system and PI3-K signalling. Moreover, it is shown for the first time that glucose induced lymphocyte survival by NF- κ B activation and down-regulation of p53 and caspase-3 (Bonilla-Ramirez, L., Jimenez-De-Rio, M. & Velez-Pardo, C. (2011). Unpublished observations). Taken altogether these results suggest that antioxidants (e.g. cannabinoids), growth factors (e.g. IGF-1) and environmental factor (e.g. glucose) might regulate cell death in lymphocytes upon oxidative stress. Unfortunately, lymphocytes as *in vitro* model of PD do not provide information about executive functions (i.e. cognitive process), kinesthesia (i.e. physical movement) and/or diet-related to PD. To further study the effect of xenotoxicity, diet and movement alterations, we therefore turn our attention to *Drosophila melanogaster*.

2.2 *Drosophila melanogaster*: an unexpected invertebrate in scene

During the last few years, *Drosophila melanogaster* has been recognized as a valuable model to study neurodegenerative diseases (Lu, 2009; Hirth, 2010), especially PD (Botella et al., 2009; Guo, 2010; Whitworth, 2011) for three main reasons. First, some genes implicated as causative of PD have at least one homolog in the fly (e.g. *parkin*, *DJ-1*, *PINK*::see <http://superfly.ucsd.edu> for further information). This unique feature has facilitated the functional interpretation of these genes in the human (Park et al., 2009; Bayersdorfer et al., 2010). Second, the expression of PD related genes in *Drosophila* can be performed by using the binary GAL-4-dependent upstream activating sequence (GAL4/UAS) system (Phelps & Brand, 1998), thus providing an excellent tool to express pathological proteins in the fly's brain (e.g. α -synuclein, Feany & Bender, 2000). Third, the dopaminergic system of the fly is well characterised (Mao & Davis, 2009; White et al., 2010). Furthermore, comparable to the human condition, the *Drosophila* DA system is also involved in locomotor control (Riemensperger et al., 2011). Therefore, the similarity between the dopaminergic network, mode of drug action and behaviour in *D. melanogaster* and mammalian systems, has made the fly a very attractive model for anti-parkinsonism drug discovery (Whitworth et al., 2006). Additionally, *Drosophila* offers the power of rapid drug screening (Pendleton et al., 2002a; Faust et al., 2009). Amazingly, a variety of approaches have been used to model Parkinson's-like motor dysfunction in *Drosophila*, including specific genetic alterations (Feany & Bender, 2000; Pendleton et al., 2002b; Wang et al., 2007; Sang et al., 2007); pharmacological inhibition of crucial proteins in the dopamine system (Pendleton et al., 2002 a, b) or pharmacological insult (Coulom et al., 2004; Chaudhuri et al., 2007). Indeed, previous studies have demonstrated that paraquat (PQ) induces selective cell death of dopaminergic neurons (Chaudhuri et al., 2007) through interaction with complex I of the mitochondrial respiratory chain (Cocheme & Murphy, 2008) and oxidative stress (Bonilla et al., 2006). Therefore, on the understanding that the causes of PD are mainly oxidative stress and mitochondrial dysfunction, antioxidants, free radical scavengers, monoamine oxidase inhibitors, iron-chelators, and other such drugs are expected to be used. The study of

antioxidants is becoming one of the most important subjects in PD research. Based on our *in vitro* data, we investigated the effect of cannabinoids and polyphenols, which are defined as a group of chemical substances present in plants, fruits and vegetables characterized by the presence of one or more than one phenol unit per molecule with several hydroxyl groups on aromatic rings, in *Drosophila melanogaster* against PQ-induced oxidative stress.

Recently, we have shown for the first time that CP55,940, a non-selective CB1/CB2 cannabinoid receptor agonist, significantly protects and rescues *Drosophila* against PQ toxicity via a receptor-independent mechanism (Fig. 7). Interestingly, CP55,940 restores the negative geotaxis activity (i.e., climbing capability) of the fly exposed to PQ. Moreover, *Drosophila* fed with (1–200 μ M) SP600125, a specific inhibitor of the stress responsive Jun-N-terminal kinase (JNK) signalling, and 20 mM PQ increased survival percentage and movement function (i.e., climbing capability) when compared to flies only treated with PQ. Taken together our results suggest that exogenous antioxidant cannabinoids can protect against and rescue from locomotor dysfunction in wild type (Canton-S) *Drosophila* exposed to stress stimuli (Jimenez-Del-Rio et al., 2008). Therefore, cannabinoids may offer promising avenues for the design of molecules to prevent, delay, or ameliorate the treatment of population at high risk of suffering Parkinson disease.

Polyphenols are a group of chemical substances found in plants classified according to their chemical structural as (i) phenolic acids such as gallic (GA), caffeic (CA), coumaric (CouA), ferulic acid (FA), propyl gallate (PG); (ii) flavonoids, which are the largest group of polyphenols, and (iii) non-flavonoid polyphenols. Flavonoids involve anthocyanins and anthoxantins. The latter group is divided into flavonols, flavans, flavanols such as epicatechin (EC), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG), flavones and isoflavones (D'Archivio et al., 2007). Numerous studies in the past decade have shown that polyphenols have *in vitro* and *in vivo* activity by preventing or reducing the deleterious effects of ROS associated with oxidative stress and neurodegeneration not only because of their strong antioxidant and metal-chelating properties (Sestili et al., 2002; Melidou et al., 2005; Perron & Brumaghim, 2009), but also because of their capability to induce intracellular signalling pathways associated with cell survival and gene expression (Ramassamy, 2006; Zaveri, 2006). We demonstrated for the first time that pure polyphenols GA, FA, CA, CouA, PG, EC, EGC, and EGCG protect, rescue and, most importantly, restore the impaired movement activity (i.e., climbing capability) induced by paraquat in *Drosophila melanogaster* (Fig. 8). We also showed for the first time that high concentrations of iron (e.g. 15 mM FeSO₄) were able to diminish fly survival and movement to a similar extent as (20 mM) paraquat treatment. Moreover, paraquat and iron synergistically affect both survival and locomotor function. Remarkably, propyl gallate and epigallocatechin gallate protected and maintained movement abilities in flies co-treated with paraquat and iron. Our findings indicate that pure polyphenols might be potent neuroprotective agents for the treatment of PD against stressful stimuli (Jimenez-Del-Rio et al., 2010).

It is generally accepted that the causes of PD are mainly oxidative stress, abnormal protein aggregation and mitochondrial dysfunction. Furthermore, substantial evidence suggests diet (Chen et al., 2007) and environmental risk factors such as pesticides (Dick et al., 2007) and heavy metals (Jones & Miller, 2008), in particular iron intake (Logroscino et al., 2008), as causative of PD. However, how genetic and environmental factors are related to the nutritional status of PD patients is still unknown. Moreover, it has not yet been definitively established whether the nutritional status of PD patients might contribute to the




Fig. 7. Protective effect of antioxidants in *Drosophila m.* exposed to paraquat.

Female flies were pre-fed with either 1% glucose alone, 0.5 mM CP55,940 or 0.5 mM vitamin E with 1% glucose in dW for 72 h. Then, flies were left untreated (GLU) or treated with 20 mM paraquat (PQ; vit E + PQ; CP + PQ) for 6, 12, 24 and 48 h. (A) Survival rate (%) and (B) locomotion assay were recorded at the indicated time. * $p < 0.05$, ** $p < 0.001$. Jimenez-Del-Rio et al., 2008. Reproduced with permission from Elsevier.




Fig. 8. Protective effect of polyphenols in *D. melanogaster* exposed to paraquat. (A) Female flies were pre-fed with either 1% glucose alone or with 0.1 mM gallic acid (GA), ferulic acid (FA), caffeic acid (CA), coumaric acid (CouA), propyl gallate (PG), epicatechin (EC), epigallocatechin (EGC), epigallocatechin gallate (EGCG) polyphenols and 0.1 mg/ml Stalevo® with 1% glucose in distilled water (dW) for 72 h. Then, flies were left untreated (U) or treated with 20mM paraquat (PQ) for 24 and 48 h. Survival rate (%) and (B) locomotion assay were recorded at the indicated time. * $p < 0.05$, ** $p < 0.001$. Jimenez-Del-Rio et al., 2010. Reproduced with permission from Elsevier.

development of the disorder. Therefore, we investigated the effect of glucose in *Drosophila melanogaster* under oxidative stress stimuli.

We have shown that female *D. melanogaster* fed acutely with 20mM PQ in high concentration of glucose (e.g. 10%), as the sole energetic source, not only prolonged survival but also the locomotor activity remained unaltered when compared to fly fed with low concentration of glucose (e.g. 1%) and PQ over a period of 24-48 h (Fig. 9). Additionally, we found that polyphenols protect, rescue and restore the impaired movement activity in *Drosophila* induced by 20 mM PQ in 1% glucose for 24 h exposure (Fig. 8). We also showed that high concentrations of iron (e.g. 10-20 mM FeSO₄) were able to diminish fly survival and locomotor activity over a period of 120 h (5 days). Taken together these findings suggest that either glucose or polyphenols might modulate life span and movement capabilities in *D. melanogaster* exposed to PQ and iron in short time frame. Since there is compelling evidence that shows that the pre-clinical period of PD extends at least 20 years before the motor manifestations (Savica et al., 2010), it is necessary to establish a close parallel with the fly to better understand antioxidant therapy approaches over long period of time. Therefore, we studied the life span and locomotor activity (i.e. climbing capability) of *D. melanogaster* chronically exposed to increasing concentrations of PQ and iron alone or in combination upon 1% or 10% glucose feeding regimen for 15 days and determined whether polyphenols such as GA, PG, EC and EGCG affect the life span and locomotor activity of the fly exposed to PQ for 15 days. It is known that protein aggregation is associated to PD (Tan et al., 2009). Interestingly, high expression levels of the transcription GAL4 protein in *D. melanogaster* have been shown to result in reduced life span (Haywood et al., 2002). Therefore, by using *Ddc-GAL4 Drosophila melanogaster* line, we also investigated whether genetically altered *Ddc-GAL4* flies renders them sensitive to PQ-induced oxidative stress and whether glucose and polyphenols might modulate life span and/or locomotor activity in this line of *Drosophila melanogaster*.




Fig. 9. Effect of glucose concentration in *Drosophila m.* exposed to paraquat.

Male (M) and female (F) were either pre-fed with 1, 5 or 10% glucose (GLU) in distilled water for 72 h. Then, flies were treated with 20 mM paraquat (PQ) for 24 and 48 h. Survival rate (%) was recorded at the indicated time. * $p < 0.05$, ** $p < 0.001$. Jimenez-Del-Rio et al., 2008. Reproduced with permission from Elsevier.

We found for the first time that polyphenols exposure prolong life span ($P < 0.05$ by log-rang test) and restore locomotor activity (i.e., climbing capability, $P < 0.05$ by χ^2 test) of *Drosophila melanogaster* chronically exposed to paraquat compared to flies treated with paraquat alone in 1% glucose (Fig. 10). We found that (10%) glucose partially prolongs life span and climbing in *Drosophila* exposed to iron, PQ or in combination, suggesting that both stimuli enhance a movement disorder in a concentration-dependent and temporal-related fashion. Moreover, chronic exposure of (1 mM) PQ/ (0.5 mM) iron synergistically affect both survival and locomotor function independently of the temporal order of the exposure to the toxicants, but the survival is modulated in a concentration and temporal fashion by glucose. This investigation is the first to report that *Ddc-GAL4* transgenic flies chronically fed with polyphenols increase life span ($P < 0.05$ by log-rang test) and enhance movement abilities ($P < 0.05$ by χ^2 test) compared to untreated *Ddc-GAL4* or treated with paraquat in 1% glucose. Our present findings support the notion that *Drosophila melanogaster* might be a suitable model to study genetic, environmental and nutritional factors as causal and/or modulators in the development of PD. Most importantly, according to our model, we have demonstrated for the first time chronic polyphenols exposure as potential therapeutic compounds in the treatment of PD. These findings altogether open new avenues for the screening, testing and development of novel antioxidant drugs against oxidative stress stimuli (Ortega-Arellano et al., 2011).

3. Conclusion

As noted by the Nobel Prize laureate Dr. S. Brenner (2002) "...choosing the right organism for one's research is as important as finding the right problems to work on..." In this regard, human peripheral blood lymphocytes and *Drosophila melanogaster* as model system are well validated and permit totally controlled experiments, are relatively low cost and ease to use, but most importantly, they resemble neuronal cells and clinical manifestation from PD patients, respectively. As any other model (e.g. animal or human tissue and cell lines), their limitation is your removal from the reality of the whole, integrated physiologic system. Despite this drawback, it turns out that their use in complex biologic investigations such as the one presented in this chapter, introduce lymphocytes and *Drosophila* as a unique opportunity to integrate oxidative stress, cell death, cell survival signalling and therapeutic pathways signalling in a single-cell and organism model.

Our present data support the notion that *Drosophila melanogaster* might be a suitable model to study genetic, environmental and nutritional factors as causal and/or modulators in the development of PD. Most importantly, according to our model, we have demonstrated for the first time that acute cannabinoids or chronic polyphenols exposure as potential therapeutic compounds in the treatment of PD.

These findings altogether open new avenues for the screening, testing, monitoring and development of novel antioxidant drugs against oxidative stress stimuli. Furthermore, based on our present findings, we propose that a combined therapy with antioxidant and high energetic agents should provide to pre-clinical genetically individuals at risk to suffer PD a means to delay or to prevent motor symptoms and/or frank PD-ARJP disorders, as those encounter in Antioquia, Colombia (Pineda-Trujillo et al., 2001, 2006, 2009). These data may contribute to a better understanding of the inherent nutritional status, genetic predisposition and environmental agents as causative factors of PD. However, further studies are needed to fully determine target selection and validation, pharmacology, measurement of efficacy




Fig. 10. Survival (A) and locomotor activity (B) of *Drosophila melanogaster* in absence (0, gray bar) or presence of paraquat (1mM) alone (black bar) or in combination of polyphenols (epicatechin (EC, 0.1 mM, red bar) or epigallocatechin gallate, EGCG gallate (0.1 mM, blue bar) in 1% glucose. Female flies (n= 50 per treatment) were treated as described in *Materials and Methods* section. The graphs show that the proportion of survival and climbing performance dramatically increased in flies exposed to polyphenols compared to PQ treatment alone. Statistical comparisons between treated flies with PQ and polyphenols and PQ alone showed (A) a $P < 0.001$ by log-rank test and (B) a $P < 0.05$ by χ^2 test. Ortega-Arellano et al., 2011. Reproduced with permission from Elsevier.

(Kieburtz & Ravina, 2007) and bioavailability (D'Archivio et al., 2010) of potential antioxidant molecules, particularly cannabinoids and polyphenols, before one can envision a preventive and effective neuroprotectant therapy against PD.

4. Acknowledgements

This work was supported by Colciencias grants #1115-343-19119 & #1115-408-20504; Programa Jovenes Investigadores from Colciencias #8790-018-2011; "Proyecto Investigaciones Enfermedades Neurodegenerativas" grants #8780, and "Programa de Sostenibilidad grants 2007/2008/2009/2010" to CV-P and MJ-Del-Rio.

5. References

- Aleyasin, H., Cregan, SP., Lyrhiaro, G., O'Hare, MJ., Callaghan, SM., Slack, RS. & Park, DS. (2004). Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage, *J Neurosci* 24: 2963-2973.
- Alves, G., Forsaa, EB., Pedersen, KF., Dreetz-Gjerstad, M. & Larsen, JP. (2008). Epidemiology of Parkinson's disease, *J Neurol* 255 Suppl 5:18-32.
- Amenta, F., Bronzetti, E., Felici, L., Ricci, A. & Tayebati, SK. (1999). Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study, *J Auton Pharmacol* 19:151-159.
- Amenta, F., Bronzetti, E., Cantalamessa, F., El-Assouad, D., Felici, L., Ricci, A. & Tayebati, SK. (2001). Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes, *J Neuroimmunol* 117 (1-2):133-142.
- Asanuma, M., Miyazaki, I., Diaz-Corrales, FJ. & Ogawa, N. (2004). Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism, *Acta Med Okayama* 58: 221-233.
- Avila-Gomez, I.C., Velez-Pardo, C. & Jimenez-Del-Rio, M. (2010). Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in lymphocyte cells, *Basic Clin Pharmacol Toxicol* 106(1): 53-61.
- Bayersdorfer, F., Voigt, A., Schneuwly, S. & Botella, JA. (2010). Dopamine-dependent neurodegeneration in *Drosophila* models of familial and sporadic Parkinson's disease, *Neurobiol Dis* 40(1):113-119.
- Betarbet, R; Sherer, TB & Greenamyre, JT. (2005). Ubiquitin-proteasome system and Parkinson's disease, *Exp Neurol* 191 Suppl 1: S17-S27.
- Battisti, C., Formichi, P., Radi, E. & Federico, A. (2008). Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to alpha-synuclein mutation, *J Neurol Sci* 267(1-2):120-124.
- Bernstein, AI., Garrison, SP., Zambetti, GP. & O'Malley, KL. (2011). 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death, *Mol Neurodegener* 6(1):2.
- Bonilla, E., Medina-Leendertz, S., Villalobos, V., Molero, L. & Bohórquez, A. (2006). Paraquat-induced oxidative stress in *drosophila melanogaster*: effects of melatonin, glutathione, serotonin, minocycline, lipoic acid and ascorbic acid, *Neurochem Res* 31(12):1425-1432.

- Botella, JA., Bayersdorfer, F., Gmeiner, F. & Schneuwly, S. (2009). Modelling Parkinson's disease in *Drosophila*, *Neuromolecular Med* 11(4):268-280.
- Bove, J., Prou, D., Perier, C. & Przedborski, S. (2005). Toxin-induced Models of Parkinson' disease, *NeuroRx* 2:484-494.
- Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, AL., Sadoul, R. & Verna, JM. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease, *Prog Neurobiol* 65:135-172.
- Brenner, S. (2002). Nature's gift to science. Nobel lecture, December 8, (www.nobelprize.com).
- Büeler, H. (2010). Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease, *Apoptosis* 15(11):1336-1353.
- Calopa, M., Bas, J., Callén, A. & Mestre, M. (2010). Apoptosis of peripheral blood lymphocytes in Parkinson patients, *Neurobiol Dis* 38(1):1-7.
- Carrillo-Vico, A., Calvo, JR., Abreu, P., Lardone, PJ., Garcia-Maurino, S., Reiter, RJ. & Guerrero, JM. (2004). Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance, *FASEB J* 18: 537-539.
- Cocheme, HM. & Murphy, MP. (2008). Complex I is the major site of mitochondrial superoxide production by paraquat, *J Biol Chem* 283: 1786-1798.
- Cookson, MR. (2010). Unravelling the role of defective genes, *Prog Brain Res* 183:43-57.
- Coulom, H. & Birman, S. (2004). Chronic exposure to rotenone models sporadic Parkinson's disease in *Drosophila melanogaster*, *J Neurosci* 24:10993-10998.
- Chaudhuri, A., Bowling, K., Funderburk, C., Lawal, H., Inamdar, A., Wang, Z. & O'Donnell, JM. (2007). Interaction of genetic and environmental factors in a *Drosophila* parkinsonism model, *J Neurosci* 27:2457-2467.
- Chen, Y. & Buck, J. (2000). Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism, *J Pharmacol Exp Ther* 293: 807-812.
- Chen, H., O'Reilly, E., McCullough, ML., Rodriguez, C., Schwarzschild, MA., Calle, EE., Thun, MJ. & Ascherio, A. (2007). Consumption of dairy products and risk of Parkinson's disease, *Am J Epidemiol* 165(9):998-1006.
- Choi, WS., Abel, G., Klintworth, H., Flavell, RA. & Xia, Z. (2010). JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death, *J Neuropathol Exp Neurol* 69(5):511-520.
- Chowdhury, I., Tharakan, B. & Bhat, GK. Caspases- an update, *Comp Biochem Physiol B Biochem Mol Biol* 2008;151(1):10-27.
- Cuervo, AM., Wong, ES. & Martinez-Vicente, M. (2010). Protein degradation, aggregation, and misfolding, *Mov Disord* 25 Suppl 1:S49-S54.
- D'Archivio, M., Filesi, C., Di Benedetto, R., Gargiulo, R., Giovannini, C. & Masella, R. (2007). Polyphenols, dietary sources and bioavailability, *Ann Ist Super Sanita* 43(4):348-361.
- D'Archivio, M., Filesi, C., Vari, R., Scazzocchio, B. & Masella R. (2010). Bioavailability of the polyphenols: status and controversies, *Int J Mol Sci* 11(4):1321-1342.
- Demuth, DG. & Molleman, A. (2006). Cannabinoid signalling, *Life Sci* 78: 549-563.
- Dexter, DT., Wells, FR., Lees, AJ., Agid, F., Agid, Y., Jenner, P. & Marsden, CD. (1989). Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, *J Neurochem* 52:1830-1836.

- Dick, FD., De Palma, G., Ahmadi, A., Scott, NW., Prescott, GJ., Bennett, J., Semple, S., Dick, S., Counsell, C., Mozzoni, P., Haites, N., Wettinger, SB., Mutti, A., Otelea, M., Seaton, A., Soderkvist, P., Felice A, & Geoparkinson study group. (2007). Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study, *Occup Environ Med* 64:666-672.
- Dorsey, ER., Constantinescu, R., Thompson, JP., Biglan, KM., Holloway, RG., Kieburtz, K., Marshall, FJ., Ravina, BM., Schifitto, G., Siderowf, A. & Tanner CM. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, *Neurology* 68(5):384-386.
- Elsohly, MA. & Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids, *Life Sci* 78: 539-548.
- Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A. & Nagata, S. (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature* 391: 43-50. Erratum in: *Nature* 1998; 393:396.
- Evans, JR. & Barker, RA. (2008). Neurotrophic factors as a therapeutic target for Parkinson's disease, *Expert Opin Ther Targets* 12(4):437-447.
- Fahn, S. & Cohen, G. (1992). The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, *Ann Neurol* 32: 804-812.
- Faraj, BA., Olkowski, ZL. & Jackson, RT. (1991). Binding of [3H]-dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites, *Pharmacology* 42:135-141.
- Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, MF. & Lu, B. (2009). Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a *Drosophila* model of Parkinson's disease, *BMC Neurosci* 10:109.
- Feany, MB. & Bender, WW. (2000). A *Drosophila* model of Parkinson's disease, *Nature* 404:394-398.
- Feng, J., Tamaskovic, R., Yang, Z., Brazil, DP., Merlo, A., Hes, D. & Hemmings, BA. (2004). Stabilization of Mdm2 via decreased ubiquitination is mediated by protein Kinase/Akt-dependent phosphorylation. *J Biol Chem* 279: 35510-35517.
- Forno, LS. (1996). Neuropathology of Parkinson's disease, *J Neuropathol Exp Neurol* 55:259-272.
- García-Arencibia, M., García, C. & Fernández-Ruiz, J. (2009). Cannabinoids and Parkinson's disease, *CNS Neurol Disord Drug Targets* 8(6):432-439.
- Gomez Del Pulgar, T., Velasco, G. & Guzman, M. (2000). The CB 1 cannabinoid receptor is coupled to the activation of protein kinase B/ Akt, *Biochem J* 347: 369-373.
- Gomez Del Pulgar, T., de Ceballos, ML., Guzman, M. & Velasco, G. (2002). Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway, *J Biol Chem* 277: 36527-36533.
- Guo, M. (2010). What have we learned from *Drosophila* models of Parkinson's disease? *Prog Brain Res* 184:3-16.
- Griffiths, PD., Dobson, BR., Jones, GR. & Clarke, DT. (1999). Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy, *Brain* 122 (Pt 4):667-673.

- Halenbeck, R., MacDonald, H., Roulston, A., Chen, TT., Conroy, L. & Williams, LT. (1998). CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45, *Curr Biol* 8: 537-540.
- Hampson, AJ., Grimaldi, M., Axelrod, J. & Wink, D. (1998). Cannabidiol and (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidants, *Proc Natl Acad Sci USA* 95: 8268-8273.
- Hardy, J. (2010). Genetic analysis of pathways to Parkinson disease, *Neuron* 68(2):201-206.
- Haywood, A.F.M., Saunders, LD. & Staveley, BE. (2002). Dopa decarboxylase (Ddc)-GAL4 dramatically reduces life span, *Dros Inf Serv* 85: 42-45.
- Heck, S., Lezoualc'h, F., Engert, S. & Behl, C. (1999). Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor κ B, *J Biol Chem* 274:9828-9835.
- Herrup, K., Neve, R., Ackerman, SL & Copani, A. (2004). Divide and die: cell cycle events as triggers of nerve cell death, *J Neurosci* 24:9232-9239.
- Hirth, F. (2010). *Drosophila melanogaster* in the study of human neurodegeneration, *CNS Neurol Disord Drug Targets* 9(4):504-523.
- Imai, Y., Soda, M. & Takahashi, R. (2000). Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity, *J Biol Chem* 275: 35661-35664.
- Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis, *J Neurol Neurosurg Psychiatry* 79(4):368-376.
- Jenner, P. & Olanow, W. (1996). Oxidative stress and the pathogenesis of Parkinson's disease. *Neurology* 47 (Suppl. 3):S161-S170.
- Jenner, P. & Olanow, CW. (1998). Understanding cell death in Parkinson's disease. *Ann Neurol.* 44 (3 Suppl 1):S72-S84.
- Jiang, H., Ren, Y., Zhao, J. & Feng, J. (2004). Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis, *Human Mol Genet* 13:1745-1754.
- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2000). Molecular mechanism of monoamine toxicity in Parkinson's disease: A hypothetical cell death model, *Medic Hypotheses* 54: 269-274.
- Jimenez-Del-Rio, M & Velez-Pardo, C. (2001). 17 β -Estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism Implication in Parkinson's disease, *Gen Pharmacol* 35: 1- 9.
- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2002). Monoamine neurotoxin-induced apoptosis in lymphocytes by a common mechanism: involvement of hydrogen peroxide (H₂O₂), caspase-3, and nuclear factor kappa-B (NF- κ B), p53, c-Jun transcription factor, *Biochem Pharmacol* 63: 677-688.
- Jimenez-Del-Rio, M., Moreno, S., Garcia-Ospina, G., Buritica, O., Uribe, CS., Lopera, F. & Velez-Pardo, C. (2004). Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine and iron-mediated apoptosis, *Mov Disord* 19: 324-330.
- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2004a). The hydrogen peroxide and its importance in the Alzheimer's and Parkinson's disease, *Current Medical Chemistry- Central Nervous System Agents* 4: 279-285.

- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2004b). Transition metals-induced apoptosis in lymphocytes via hydroxyl radical generation, mitochondria dysfunction and caspase-3 activation: an *in vitro* model for neurodegeneration, *Arch Medic Res* 35:185-193.
- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2006). Insulin-like growth factor-1 prevents $A\beta_{[25-35]}$ / (H_2O_2) -induced apoptosis in lymphocytes by reciprocal NF- κ B activation and p53 inhibition via PI3K-dependent pathway. *Growth Factors* 24: 67-78.
- Jimenez-Del-Rio, M. & Velez-Pardo, C. (2008). Paraquat induces apoptosis in human lymphocytes: Protective and rescue effects of glucose, cannabinoids and Insulin-like growth factor-1, *Growth Factors* 26(1): 49-60.
- Jimenez-Del-Rio, M., Daza-Restrepo, A. & Velez-Pardo, C. (2008). The cannabinoid CP55, 940 prolongs survival and improves locomotor activity in *Drosophila melanogaster* against paraquat: implications in Parkinson's disease, *Neurosci Res* 61:404-411.
- Jimenez-Del-Rio, M., Guzman-Martinez, C. & Velez-Pardo, C. (2010). The effects of polyphenols on survival and locomotor activity in *Drosophila melanogaster* exposed to iron and paraquat, *Neurochem Res* 35(2):227-238.
- Jones, DC. & Miller, GW. (2008). The effects of environmental neurotoxicants on the dopaminergic system: a possible role in drug addiction, *Biochem Pharmacol* 76:569-581.
- Kairisalo, M., Korhonen, L., Blomgren, K. & Lindholm, D. (2007). X-linked inhibitor of apoptosis protein increases mitochondrial antioxidants through NF-kappaB activation, *Biochem Biophys Res Commun* 364(1):138-144.
- Kane, LP., Shapiro, VS., Stokoe, D. & Weiss, A. (1999). Induction of NF-kappaB by the Akt/PKB kinase. *Curr Biol*. 9: 601-604.
- Kawashima, K. & Fujii, T. (2004). Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation to the regulation of immune function, *Frontiers Biosci* 9:2063-2085.
- Kerr, JFR., Wyllie, AH. & Currie, AR. (1972). Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics, *Br J Cancer* 26: 239-257.
- Kerr, JFR., Gobe, GC., Winterford, CM. & Harmon, BV. Anatomical methods in cell death. In: Schwartz, LM. & Osborne, BA; editors. *Methods in cell biology: cell death*. New York: Academic Press; 1995; pp. 1-27.
- Kim, SH., Won, SJ., Mao, XO., Jin, K. & Greenberg, DA. (2005). Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury, *J Pharmacol Exp Ther* 313: 88-94.
- Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y. & Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, *Nature* 392:605-608.
- Kooijman, R., Willems, M., DeCarla, HJC., Rijkers, GT., Schuurmans, ALG., Van Buul-Offers, SC., Heijnen, CJ. & Zegers, BJM. (1992). Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells, *Endocrinol* 131: 2244-2250.
- Kutuk, O. & Basaga, H. (2003). Aspirin prevents apoptosis and NFkappaB activation induced by H_2O_2 in HeLa cells, *Free Radic Res* 37:1267-1276.

- Kaplan, BL., Rockwell, CE. & Kaminski, NE. (2003). Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes, *J Pharmacol Exp Ther* 306(3):1077-1085.
- Kieburz, K. & Ravina, B. (2007). Why hasn't neuroprotection worked in Parkinson's disease? *Nat Clin Pract Neurol* 3(5):240-241.
- Kriesberg, N. (2011). Animals as models. (<http://ori.dhhs.gov/education/products/ncstate/models.htm>, available in April, 2011).
- Klegeris, A., Bissonnette, CJ. & McGeer, PL. (2003). Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. *Br J Pharmacol.* 139: 775-786.
- Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, ES., Baehrecke, EH., Blagosklonny, MV., El-Deiry, WS., Golstein, P., Green, DR., Hengartner, M., Knight, RA., Kumar, S., Lipton, SA., Malorni, W., Nuñez, G., Peter, ME., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., Melino, G. & Nomenclature Committee on Cell Death 2009. (2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009, *Cell Death Differ* 16(1):3-11.
- Levy, OA., Malagelada, C. & Greene, LA. (2009). Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps, *Apoptosis* 14(4):478-500.
- Liang, ZQ., Li, YL., Zhao, XL., Han, R., Wang, XX., Wang, Y., Chase, TN., Bennett, MC. & Qin, ZH. (2007). NF- κ B contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. *Brain Res* 1145:190-203.
- Li, LY., Zhao, XL., Fei, XF., Gu, ZL., Qin, ZH. & Liang, ZQ. (2008). Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra, *Acta Pharmacol Sin* 29(5):539-547.
- Lin, TK., Liou, CW., Chen, SD., Chuang, YC., Tiao, MM., Wang, PW., Chen, JB. & Chuang, JH. (2009). Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease, *Chang Gung Med J* 32(6):589-599.
- Liu, X., Zou, H., Slaughter, C. & Wang, X. (1997). DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis, *Cell.* 89:175-184.
- Logroschino, G., Gao, X., Chen, H., Wing A. & Ascherio, A. (2008). Dietary iron intake and risk of Parkinson's disease, *Am J Epidemiol* 168(12):1381-1388.
- Lombardi, G., Dianzani, C., Miglio, G., Canonico, PL. & Fantozzi, R. (2001). Characterization of ionotropic glutamate receptors in human lymphocytes, *Br J Pharmacol* 133: 936-944.
- Lombardi, G., Miglio, G., Dianzani, C., Mesturini, R., Varsaldi, F., Chiocchetti, A., Dianzani, U., Fantozzi, R. (2004). Glutamate modulation of human lymphocyte growth: in vitro studies, *Biochem Biophys Res Commun.* 28; 318: 496-502.
- Lu, Y. (2005). p53: a heavily dictated dictator of life and death, *Curr Opin Genet Dev* 15: 27-33.
- Lu, B. (2009). Recent advances in using *Drosophila* to model neurodegenerative diseases, *Apoptosis* 14(8):1008-1020.
- Maciver, NJ., Jacobs, SR., Wieman, HL., Wofford, JA., Coloff, JL. & Rathmell, JC. (2008). Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival, *J. Leukoc. Biol.* 84,949-957.

- Manolescu, AR., Witkowska, K., Kinnaird, A., Cessford T., Cheeseman, C. (2007). Facilitated hexose transporters: new perspectives on form and function, *Physiology (Bethesda)* 22, 234-240.
- Mao, Z. & Davis, RL. (2009). Eight different types of dopaminergic neurons innervate the *Drosophila* mushroom body neuropil: anatomical and physiological heterogeneity, *Front Neural Circuits* 3:5.
- Marazziti, D., Consoli, G., Masala, I., Catena Dell'Osso, M. & Baroni, S. (2010). Latest advancements on serotonin and dopamine transporters in lymphocytes, *Mini Rev Med Chem* 10(1):32-40.
- Marini, M., Frabetti, F., Canaider, S., Dini, L., Falcieri, E. & Poirier, GG. (2001). Modulation of caspase-3 activity by zinc ions and by the cell redox state, *Exp Cell Res* 266:323-332.
- Marino, F., Cosentino, M., Bombelli, R., Ferrari, M., Lecchini, S. & Frigo, G. (1999). Endogenous catecholamine synthesis, metabolism, storage, and uptake in human peripheral blood mononuclear cells, *Exp Hematol* 27:489-495.
- Marsicano, G., Moosmann, B., Hermann, H., Lutz, B. & Behl, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1, *J Neurochem* 80: 448-456.
- Massoud, TF., Hademenos, GJ., Young, WL., Gao, E., Pile-Spellman, J., Viñuela, F. (1998). Principles and philosophy of modeling in biomedical research, *FASEB J* 12(3):275-285.
- Matsuda, LA., Lolait, SJ., Brownstein, M., Young, A. & Bonner, TI. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA, *Nature* 346: 561-564.
- Melidou, M., Riganakos, K. & Galaris, D. (2005). Protection against nuclear DNA damage offered by flavonoids in cells exposed to hydrogen peroxide: the role of iron chelation, *Free Radic Biol Med* 39:1591-1600.
- Miglio, G., Varsaldi, F., Dianzani, C., Fantozzi, R. & Lombardi, G. (2005). Stimulation of group I metabotropic glutamate receptors evokes calcium signals and c-jun and c-fos gene expression in human T cells, *Biochem Pharmacol* 70:189-199.
- Migliore, L., Petrozzi, L., Lucetti, C., Gambaccini, G., Bernardini, S., Scarpato, R., Trippi, F., Barale, R., Frenzilli, G., Rodilla, V. & Bonuccelli, U. (2002). Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients, *Neurology* 58: 1809-1815.
- Miyashita, T. & Reed, JC. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene, *Cell* 80: 293-299.
- Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Almazan, G., Molina-Holgado, F., Borrell, J. & Guaza, C. (2002). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling, *J Neurosci* 22: 9742-9753.
- Munro, S., Thomas, KL. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids, *Nature* 365: 61-65.
- McKenna, F., McLaughlin, PJ., Lewis, BJ., Sibbring, GC., Cummerson, JA., Bowen-Jones, D. & Moots, RJ. (2002). Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study, *J Neuroimmunol.* 132 (1-2):34-40.

- Nagayama, T., Sinor, AD., Simon, RP., Chen, J., Graham, SH., Jin, K. & Greenberg, DA. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures, *J Neurosci* 19: 2987-2995.
- Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N. & Gotoh, Y. (2002). Akt enhances Mdm2-mediated Ubiquitination and degradation of p53, *J Biol Chem* 277: 21843-21850.
- Ortega-Arellano, HF., Jimenez-Del-Rio, M. & Velez-Pardo, C. (2011). Life span and locomotor activity modification by glucose and polyphenols in *Drosophila melanogaster* chronically exposed to oxidative stress-stimuli: Implications in Parkinson's disease, *Neurochem Res* 36: 1073-1086.
- Padgett, LW. (2005). Recent developments cannabinoid ligands, *Life Sci* 77: 1767-1798.
- Pendleton, RG., Parvez, F., Sayed, M., Hillman, R. (2002a). Effects of pharmacological agents upon a transgenic model of Parkinson's disease in *Drosophila melanogaster*, *J Pharmacol Exp Ther* 300:91-96.
- Pendleton, RG., Rasheed, A., Sardina, T., Tully, T. & Hillman, R. (2002b). Effects of tyrosine hydroxylase mutants on locomotor activity in *Drosophila*: a study in functional genomics, *Behav Genet* 32: 89-94.
- Park, J., Kim, Y., Chung, J. (2009). Mitochondrial dysfunction and Parkinson's disease genes: insights from *Drosophila*, *Dis Model Mech* 2(7-8):336-340.
- Pazos, MR., Nunez, E., Benito, C., Tolon, RM. & Romero, J. (2005). Functional neuroanatomy of the endocannabinoid system, *Pharmacol Biochem Behav* 81:239-247.
- Perron, NR. & Brumaghim, JL. (2009). A review of the antioxidant mechanisms of polyphenol compounds related to iron binding, *Cell Biochem Biophys* 53:75-100.
- Phelps, CB. & Brand, AH. (1998). Ectopic gene expression in *Drosophila* using GAL4 system, *Methods* 14(4):367-379.
- Piatkiewicz, P., Czech, A. & Tatoń, J. (2007). Glucose transport in human peripheral blood lymphocytes influenced by type 2 diabetes mellitus, *Arch. Immunol. Ther. Exp. (Warsz)* 55,119-126.
- Pineda-Trujillo, N., Carvajal-Carmona, LG., Buritica, O., Moreno, S., Uribe, C., Pineda, D., Toro, M., Garcia, F., Arias, W., Bedoya, G., Lopera, F. & Ruiz-Linares, A. (2001). A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of juvenile Parkinsonism in a population from North West Colombia, *Neurosci Lett* 298: 87-90.
- Pineda-Trujillo, N., Apergi, M., Moreno, S., Arias, W., Lesage, S., Franco, A., Sepulveda-Falla, D., Cano, D., Buritica, O., Pineda, D., Uribe, CS., de Yebenes, JG., Lees, AJ., Brice, A., Bedoya, G., Lopera, F. & Ruiz-Linares, A. (2006). A genetic cluster of early onset Parkinson's disease in a Colombian population, *Am J Med Genet B Neuropsychiatr Genet* 141B(8):885-888.
- Pineda-Trujillo, N., Dulcey-Cepeda, A., Arias-Pérez, W., Moreno-Masmela, S., Saldarriaga-Henao, A., Sepúlveda-Falla, D., Bedoya-Berrío, G., Lopera-Restrepo F. & Ruiz-Linares, A. (2009). Una mutación en el gen *PARK2* causa enfermedad de Parkinson juvenil en una extensa familia colombiana, *IATREIA* 22(2): 122-131.
- Polymeropoulos, MH., Lavedan, C., Leroy, E., Ide, SE., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, ES., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, WG., Lazzarini, AM., Duvoisin, RC., Di Iorio G., Golbe LI. & Nussbaum, RL. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, *Science* 27; 276:2045-2047.

- Prabhakaran, K., Ghosh, D., Chapman, GD. & Gunasekar, PG. (2008). Molecular mechanism of manganese exposure-induced dopaminergic toxicity, *Brain Res Bull* 76(4):361-367.
- Pradilla, AG., Vesga, ABE., León-Sarmiento, FE; GENECO. (2003). [National neuroepidemiological study in Colombia (EPINEURO)], *Rev Panam Salud Publica* 14(2):104-11.
- Prasad, S., Ravindran, J. & Aggarwal, BB. (2010). NF-kappaB and cancer: how intimate is this relationship, *Mol Cell Biochem* 336(1-2):25-37.
- Przedborski, S. (2005). Pathogenesis of nigral cell death in Parkinson's disease, *Parkinsonism Relat Disord* 11 Suppl 1:S3-S7.
- Prigione, A., Isaias, IU., Galbussera, A., Brighina, L., Begni, B., Andreoni, S., Pezzoli, G., Antonini, A., Ferrarese, C. (2009). Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients, *Parkinsonism Relat Disord* 15(4):327-328.
- Qin, ZH., Tao, LY. & Chen, X. (2007). Dual roles of NF-kappaB in cell survival and implications of NF-kappaB inhibitors in neuroprotective therapy, *Acta Pharmacol Sin* 28(12):1859-72.
- Quesada, A., Lee, BY. & Micevych, PE. (2008). PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease, *Dev Neurobiol* 68(5):632-644.
- Ramassamy, C. (2006). Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets, *Eur J Pharmacol* 545:51-64.
- Ricci, A. & Amenta, F. (1994). Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study, *J Neuroimmunol* 53: 1-7.
- Ricci, A., Veglio, F. & Amenta, F. (1995). Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with {3H} 7OH-DPAT, *J Neuroimmunol* 58: 139-144.
- Ricci, A., Bronzetti, E., Felici, L., Tayebati, SK. & Amenta, F. (1997). Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study, *Neurosci Lett* 229: 130-134.
- Riederer, P., Dirr, A., Goetz, M., Sofic, E., Jellinger, K. & Youdim, MB. (1992). Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease, *Ann Neurol* 32 Suppl: S101-S104.
- Riemensperger, T., Isabel, G., Coulom, H., Neuser, K., Seugnet, L., Kume, K., Iché-Torres, M., Cassar, M., Strauss, R., Preat, T., Hirsh, J. & Birman, S. (2011). Behavioral consequences of dopamine deficiency in the *Drosophila* central nervous system, *Proc Natl Acad Sci U S A* 108(2):834-839.
- Sanchez, MG., Ruiz-Llorente, L., Sanchez, AM. & Diaz-Leviada, I. (2003). Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction, *Cell Signal* 15: 851-859.
- Sanchez, JL., Buritica-Henao, O., Pineda Salazar, DA., Ribe, CS. & Palacio-Baena, LG. (2004). Prevalence of Parkinson's disease and Parkinsonism in a Colombian population using the capture recapture methods. *Int J Neurosci* 113:175-182.
- Sanders, VM. (1998). The role of norepinephrine and beta-2 adrenergic receptor stimulation in the modulation of Th1, Th2, and B lymphocyte function, *Adv Exp Med Biol* 437:269-278.

- Sang, TK., Chang, HY., Lawless, GM., Ratnaparkhi, A., Mee, L., Ackerson, LC., Maidment, NT., Krantz, DE. & Jackson, GR. (2007). A *Drosophila* model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine, *J Neurosci* 27:981-992.
- Sakahira, H., Enari, M. & Nagata, S. (1998). Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis, *Nature* 391: 96-99.
- Sakahira, H., Enari, M., Ohsawa, Y., Uchiyama, Y. & Nagata, S. (1999). Apoptotic nuclear morphological change without DNA fragmentation, *Curr Biol* 9: 543-546.
- Savica, R., Rocca, WA. & Ahlskog, JE. (2010). When does Parkinson disease start? *Arch Neurol* 67(7):798-801.
- Sestili, P., Diamantini, G., Bedini, A., Cerioni, L., Tommasini, I., Tarzia, G. & Cantoni, O. (2002). Plant-derived phenolic compounds prevent the DNA single-strand breakage and cytotoxicity induced by tertbutylhydroperoxide via an iron-chelating mechanism, *Biochem J* 364(Pt 1):121-128.
- Sian-Hülsmann, J., Mandel, S., Youdim, HMB. & Riederer, P. (2010). The Relevance of iron in the pathogenesis of Parkinson's Disease, *J Neurochem* doi: 10.1111/j.1471-4159.2010.07132.x.
- Sofic, E., Paulus, W., Jellinger, K., Riederer, P. & Youdim, MB. (1991). Selective increase of iron in substantia nigra zona compacta of parkinsonian brains, *J Neurochem*. 56: 978-982.
- Shishodia, S. & Aggarwal, BB. (2004). Nuclear factor kB: a friend or a foe in cancer? *Biochem Pharmacol* 68: 1071-1080.
- Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K. & Suzuki, T. (2000). Familial Parkinson disease gene product, parkin is an ubiquitin-protein ligase, *Nat Genet* 25:302-305.
- Skaper, SD., Burianni, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L. & Leon, A. (1996). The Alkamide palmitoylethanolamine and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons, *Proc Natl Acad Sci USA* 93: 3984-3989.
- Stefulj, J., Jernej, B., Cicin-Sain, L., Rinner, I. & Schauenstein K. (2000). mRNA expression of serotonin receptors in cells of the immune tissues of the rat, *Brain Behav Immun* 14(3):219-224.
- Tan, JM., Wong, ES. & Lim, KL. (2009). Protein misfolding and aggregation in Parkinson's disease, *Antioxid Redox Signal* 11(9):2119-2134.
- Takada, Y., Mukhopadhyay, A., Kundu, GC., Mahabeleshwar, GH., Singh, S. & Aggarwal, BB. (2003). Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase, *J Biol Chem* 278: 24233-24241.
- Takanashi, M., Mochizuchi, H., Yokomizo, K., Hattori, N., Mori, H., Yamamura, Y. & Mizuno, Y. (2001). Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP), *Parkinsonism Relat Disord* 7: 311-314.
- Tanaka, K., Suzuki, T., Chiba, T., Shimura, H., Hattori, N. & Mizuno, Y. (2001). Parkin is linked to the ubiquitin pathway, *J Mol Med* 79: 482-494.

- Tapson, VF., Schenetzler, B., Pilch, PF., Center, DM. & Berman, JS. (1988). Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro, *J Clin Invest* 82: 950-957.
- Tillakaratne, NJ., Medina-Kauwe, L. & Gibson, KM. (1995). Gamma Aminobutyric acid (GABA) metabolism in mammalian neural and non-neural tissues, *Comp Biochem Physiol A Physiol* 112(2):247-263.
- Thakur, GA., Duclos, RI Jr. & Makriyannis, A. (2005). Natural cannabinoids: Templates for drug discovery, *Life Sci* 78: 454-466.
- Tsang, AH. & Chung, KK. (2009). Oxidative and nitrosative stress in Parkinson's disease, *Biochim Biophys Acta* 1792(7):643-650.
- Turu, G. & Hunyady, L. (2010). Signal transduction of the CB1 cannabinoid receptor, *J Mol Endocrinol* 44(2):75-85.
- Van der Stelt, M. & Di Marzo, V. (2005). Cannabinoid receptors and their role in neuroprotection, *Neuromolecular Med.* 7(1-2):37-50.
- Van Sickle, MD., Duncan, M., Kingsley, PJ., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, JS., Marnett, LJ., Di Marzo, V., Pittman, QJ., Patel, KD. & Sharkey, KA. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors, *Science* 310:329-332.
- Velez-Pardo, C. & Jimenez-Del-Rio, M. (2006). Avoidance of A β [25-35] / (H₂O₂)-induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: Role of NF- κ B and p53, *Medicinal Chemistry* 2: 471-479.
- Velez-Pardo, C., Jimenez-Del-Rio, M., Lores-Arnaiz, S. & Bustamante, J. (2010). Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure, *Neurochemical Research* 35:1323-1332.
- Wang, C., Lu, R., Ouyang, X., Ho, M.W., Chia, W., Yu, F., & Lim, K.L. (2007). *Drosophila* overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities, *J Neurosci* 27:8563-8570.
- White, KE., Humphrey, DM., Hirth, F. (2010). The dopaminergic system in the aging brain of *Drosophila*, *Front Neurosci* 4:205.
- Wu, H; Lozano, G. (1994). NF- κ B activation of p53, *J Biol Chem* 269: 20067-20074.
- Wyllie, AH. (1980). Glucocorticoid-induced thymocytes apoptosis associated with endogenous endonuclease activation, *Nature* 284: 555-556.
- Wang, C., Lu, R., Ouyang, X., Ho, M.W., Chia, W., Yu, F., & Lim, K.L. (2007). *Drosophila* overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities, *J Neurosci* 27:8563-8570.
- Wang, X. & Michaelis, EK. (2010) Selective neuronal vulnerability to oxidative stress in the brain, *Front Aging Neurosci* 2:12.
- Whitworth, AJ., Wes, PD. & Pallanck, LJ. (2006). *Drosophila* models pioneer a new approach to drug discovery for Parkinson's disease, *Drug Discov Today* 11(3-4):119-126.
- Whitworth, AJ. (2011). *Drosophila* models of Parkinson's disease, *Adv Genet* 73:1-50.
- Xiang, H., Kinoshita, Y., Knudson, CM., Korsmeyer, SJ., Schwartzkroin, PA. & Morrison, RS. (1998). Bax involvement in p53-mediated neuronal cell death, *J Neurosci* 18(4):1363-1373.

- Xiromerisiou, G., Dardiotis, E., Tsimourtou, V., Kountra, PM., Paterakis, KN., Kapsalaki, EZ., Fountas, KN. & Hadjigeorgiou, GM. (2010). Genetic basis of Parkinson disease, *Neurosurg Focus* 28(1):E7.
- Xu, G. & Shi, Y. (2007). Apoptosis signaling pathways and lymphocyte homeostasis, *Cell Res* 17(9):759-771.
- Zaveri, NT. (2006). Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications, *Life Sci* 78:2073-2080.
- Zhang, Y., Dawson, VL. & Dawson, TM. (2001). Parkin: clinical aspects and neurobiology, *Clin Neurosci Res* 1: 467- 482.
- Zhou, C., Huang, Y., Przedborski, S. (2008). Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance, *Ann N Y Acad Sci* 1147:93-104.

IntechOpen



Mechanisms in Parkinson's Disease - Models and Treatments

Edited by Dr. Juliana Dushanova

ISBN 978-953-307-876-2

Hard cover, 582 pages

Publisher InTech

Published online 08, February, 2012

Published in print edition February, 2012

Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Marlene Jimenez-Del-Rio and Carlos Velez-Pardo (2012). Human Lymphocytes and *Drosophila melanogaster* as Model System to Study Oxidative Stress in Parkinson's Disease, *Mechanisms in Parkinson's Disease - Models and Treatments*, Dr. Juliana Dushanova (Ed.), ISBN: 978-953-307-876-2, InTech, Available from: <http://www.intechopen.com/books/mechanisms-in-parkinson-s-disease-models-and-treatments/human-lymphocytes-and-drosophila-melanogaster-as-model-system-to-study-oxidative-stress-in-parkinson>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen